IGM Biosciences cuts 22% of workforce, axes hematologic oncology program
IGM Biosciences is not only reducing its workforce by about 22%, but it is also axing its clinical development program in hematologic oncology as well as an unnamed targeted cytokine candidate.
The California-based company said the changes would extend its cash runway into the second quarter of 2026, stretching the original timeline of the second half of 2025. According to SEC filings, IGM had 290 full-time employees as of Sept. 30.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.